Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Non-Current Assets (2019 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Non-Current Assets for 7 consecutive years, with $3.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Assets rose 234.41% year-over-year to $3.2 million, compared with a TTM value of $3.2 million through Sep 2025, up 234.41%, and an annual FY2024 reading of $822000.0, up 13600.0% over the prior year.
  • Non-Current Assets was $3.2 million for Q3 2025 at Fennec Pharmaceuticals, down from $4.1 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $4.1 million in Q2 2025 and bottomed at $6000.0 in Q4 2023.
  • Average Non-Current Assets over 5 years is $907941.2, with a median of $211000.0 recorded in 2022.
  • The sharpest move saw Non-Current Assets crashed 97.16% in 2023, then skyrocketed 13600.0% in 2024.
  • Year by year, Non-Current Assets stood at $35000.0 in 2021, then soared by 502.86% to $211000.0 in 2022, then plummeted by 97.16% to $6000.0 in 2023, then surged by 13600.0% to $822000.0 in 2024, then surged by 288.93% to $3.2 million in 2025.
  • Business Quant data shows Non-Current Assets for FENC at $3.2 million in Q3 2025, $4.1 million in Q2 2025, and $3.4 million in Q1 2025.